<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194829</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-01425</org_study_id>
    <secondary_id>NCI-2014-01425</secondary_id>
    <secondary_id>E1213</secondary_id>
    <secondary_id>EA2131</secondary_id>
    <secondary_id>EA2131</secondary_id>
    <secondary_id>U10CA180820</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT02194829</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase I/II trial studies the side effects and best dose of WEE1
      inhibitor MK-1775 when given together with paclitaxel albumin-stabilized nanoparticle
      formulation and gemcitabine hydrochloride and how well they work in treating patients with
      previously untreated pancreatic cancer that has spread to another place in the body or cannot
      be removed by surgery. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized
      nanoparticle formulation and gemcitabine hydrochloride, work in different ways to stop the
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
      stopping them from spreading. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by
      blocking some of the enzymes needed for cell growth. It is not yet known whether paclitaxel
      albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride are more effective
      with or without WEE1 inhibitor MK-1775 in treating patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the toxicity of combination therapy with nab-paclitaxel (paclitaxel
      albumin-stabilized nanoparticle formulation), gemcitabine (gemcitabine hydrochloride) and
      AZD1775 (WEE1 inhibitor MK-1775) in patients with treatment-naive metastatic adenocarcinoma
      of the pancreas or locally-advanced adenocarcinoma of the pancreas which is not surgically
      resectable. (Phase I) II. To determine the dose of AZD1775 to be used in combination with
      nab-paclitaxel and gemcitabine chemotherapy in the phase II portion of the trial. (Phase I)
      III. To determine the pharmacokinetics of AZD1775 in combination with nab-paclitaxel and
      gemcitabine. (Phase I) IV. To evaluate progression-free survival (PFS) associated with
      nab-paclitaxel/gemcitabine/placebo or nab-paclitaxel/gemcitabine/AZD1775 in patients with
      metastatic adenocarcinoma of the pancreas. (Phase II)

      SECONDARY OBJECTIVES:

      I. To evaluate overall survival (OS) associated with nab-paclitaxel/gemcitabine/placebo or
      nab-paclitaxel/gemcitabine/AZD1775 in patients with metastatic adenocarcinoma of the
      pancreas. (Phase II) II. To evaluate response rate (complete response [CR] + partial response
      [PR]) associated with nab-paclitaxel/gemcitabine/placebo or
      nab-paclitaxel/gemcitabine/AZD1775 in patients with metastatic adenocarcinoma of the
      pancreas. (Phase II) III. To evaluate disease control rate (CR + PR + stable disease [SD])
      associated with nab-paclitaxel/gemcitabine/placebo or nab-paclitaxel/gemcitabine/AZD1775 in
      patients with metastatic adenocarcinoma of the pancreas. (Phase II)

      TERTIARY OBJECTIVES:

      I. To evaluate the ability of AZD1775 to inhibit Wee1 and increase deoxyribonucleic acid
      (DNA) damage and tumor cell death when combined with nab-paclitaxel/gemcitabine compared to
      nab-paclitaxel/gemcitabine/placebo. (Phase II) II. To evaluate if biomarker changes in tumor
      tissue associated with Wee1 inhibition may also be present in hair follicles. (Phase II) III.
      To evaluate the change in tumor fludeoxyglucose (FDG) uptake (maximum standardized uptake
      value [SUVmax]) between baseline FDG-positron emission tomography (PET) and week 4 FDG-PET as
      a predictor of response using Response Evaluation Criteria in Solid Tumors (RECIST) as the
      reference standard for response. (Phase II) IV. To evaluate the change in tumor FDG uptake
      (SUVmax) between baseline FDG-PET and week 4 FDG-PET as a predictor of progression-free
      survival. (Phase II) V. To compare the change in tumor FDG uptake (SUVmax) between baseline
      FDG-PET and week 4 FDG-PET between the patients from treatment arms C and D. (Phase II) VI.
      To evaluate if an early increase in tumor fluorothymidine (FLT) uptake (FLT-flare) is
      observed within 24 hours after initiation of treatment with
      nab-paclitaxel/gemcitabine/placebo. (Phase II) VII. To evaluate if an early (within 24 hours
      [h]) increase in tumor FLT uptake (FLT-flare) is abrogated after initiation of treatment with
      nab-paclitaxel/gemcitabine/AZD1775. (Phase II) VIII. To compare the change in tumor FLT
      uptake (SUVmax) from baseline to 24 hours after initiation of treatment between the patients
      from treatment arms C and D. (Phase II)

      OUTLINE: This is a phase I, dose escalation study of WEE1 inhibitor MK-1775 followed by a
      randomized phase II study. Patients in phase I are assigned to arm A or B and patients in
      phase II are randomized to arm C or D.

      ARM A (PHASE I, DOSE LEVEL 1): Patients receive paclitaxel albumin-stabilized nanoparticle
      formulation intravenously (IV) over 30 minutes and gemcitabine hydrochloride IV over 30
      minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 orally (PO) daily
      on days 1, 2, 8, 9, 15, and 16.

      ARM B (PHASE I, DOSE LEVEL 2): Patients receive paclitaxel albumin-stabilized nanoparticle
      formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.

      ARM C (PHASE II, PLACEBO): Patients receive paclitaxel albumin-stabilized nanoparticle
      formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily
      on days 1, 2, 8, 9, 15, and 16.

      ARM D (PHASE II, WEE1 INHIBITOR MK-1775): Patients receive paclitaxel albumin-stabilized
      nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.

      In all arms, courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of WEE1 inhibitor MEK-1775, defined as the highest dose level at which &lt; 33% of 6 patients experience a dose-limiting toxicity graded according to Common Terminology Criteria for Adverse Events version 4 (Phase I)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From randomization to documented progression or death without progression, assessed up to 2 years</time_frame>
    <description>PFS by arm will be compared using one-sided log-rank tests. Cox's proportional hazards models will be used to estimate hazard ratios.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to death from any cause, assessed up to 2 years</time_frame>
    <description>OS by arm will be compared using one-sided log-rank tests. Cox's proportional hazards models will be used to estimate hazard ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR + PR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be analyzed using Fisher's exact tests at a one-sided significance level of 0.15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (CR + PR + SD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be analyzed using Fisher's exact tests at a one-sided significance level of 0.15.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in tumor FDG uptake (SUVmax)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Will be evaluated as a predictor of response using RECIST as the reference standard.</description>
  </other_outcome>
  <other_outcome>
    <measure>Accuracy of change in tumor FDG uptake (SUVmax) between baseline FDG-PET and week 4 FDG-PET as a predictor of progression-free survival</measure>
    <time_frame>Up to week 4</time_frame>
    <description>Time-dependent receiver operator characteristic methodology will be used to assess the ability of SUVmax change to predict PFS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor FDG uptake (SUVmax) between baseline FDG-PET and week 4 FDG-PET</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Will be compared between the patients from treatment arms C and D only as a continuous variable using Wilcoxon test and as binary variable (defined as summed SUVmax change from baseline &lt; -25% versus &gt;= -25%) using Fisher's exact tests.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of an early increase in tumor FLT uptake (FLT-flare) within 24 hours after initiation of treatment</measure>
    <time_frame>Up to 24 hours after initiation of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of abrogation of early increase in tumor FLT uptake after initiation of treatment</measure>
    <time_frame>Up to 24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor FLT uptake (SUVmax)</measure>
    <time_frame>Baseline to 24 hours after initiation of treatment</time_frame>
    <description>Will be compared between patients from treatment arms C and D.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <condition>Stage III Pancreatic Cancer AJCC v6 and v7</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v6 and v7</condition>
  <condition>Unresectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 PO daily on days 1, 2, 8, 9, 15, and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily on days 1, 2, 8, 9, 15, and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 (recommended phase II dose) as in Arm A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adavosertib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <other_name>AZD-1775</other_name>
    <other_name>AZD1775</other_name>
    <other_name>MK-1775</other_name>
    <other_name>MK1775</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
    <other_name>paclitaxel albumin-stabilized nanoparticle formulation</other_name>
    <other_name>Protein-bound Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PHASE I STUDY -- ARM A (DOSE LEVEL 1) AND ARM B (DOSE LEVEL 2)

          -  Patients must have histologically or cytologically confirmed metastatic or
             unresectable locally advanced adenocarcinoma of the pancreas with no prior systemic
             therapy for metastatic or locally advanced disease

          -  Previous neo-adjuvant or adjuvant treatment is allowed provided that it was given &gt;= 6
             months prior to registration

          -  Patients must NOT be receiving any other investigational agents concurrently and must
             not have received any other investigational agents =&lt; 4 weeks prior to registration

          -  Patients must not have a pre-existing &gt; grade 1 motor or sensory neuropathy

          -  Patients must NOT have history of allergic reactions attributed to compounds of
             similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0
             or 1

          -  Patients must have a life expectancy of &gt;= 12 weeks

          -  Patients may have had prior radiotherapy for metastatic disease as long as it was &gt; 4
             weeks prior to registration and the patient has recovered from adverse events
             associated with the radiotherapy

          -  Patients must NOT be taking current medications or substances that are inhibitors or
             inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4)

          -  Patients must NOT have uncontrolled serious medical illness including, but not limited
             to, ongoing or active infection, cardiac arrhythmia, or psychiatric illness that would
             limit compliance with study requirements

          -  Patients with known human immunodeficiency virus (HIV) are not eligible if cluster of
             differentiation (CD)4 count is =&lt; 200 cell/mm^3 or if receiving antiretroviral therapy

          -  Patients must be able to swallow capsules whole

          -  Patients must NOT have previous or concurrent malignancy; exceptions are made for
             patients who meet any of the following conditions:

               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in situ)

               -  Prior malignancy completely excised or removed and patient has been continuously
                  disease free for &gt; 5 years

          -  Patients must be able to tolerate computed tomography (CT), magnetic resonance imaging
             (MRI) or PET imaging including contrast agents

          -  Women must not be pregnant or breast-feeding

               -  Females of childbearing potential must have a blood test or urine study within 5
                  days prior to registration to rule out pregnancy; a female of childbearing
                  potential is any woman, regardless of sexual orientation or whether they have
                  undergone tubal ligation, who meets the following criteria: 1) has not undergone
                  a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any
                  time in the preceding 24 consecutive months)

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal and barrier method of birth control; two barrier methods of birth control;
             abstinence) for the duration of study treatment and for 3 months after the last dose
             of study treatment; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately;
             should a man impregnate or suspect that he has impregnated a woman while participating
             in this study, he should inform his treating physician immediately

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Hemoglobin &gt;= 9 g/dL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin =&lt; 1.5 institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 3 X institutional upper limit of normal (ULN) or =&lt; 5 X ULN if the patient has
             liver metastases

          -  Creatinine =&lt; 1.5 mg/dL or creatinine clearance (Cockcroft-Gault) &gt;= 60 mL/min for
             patients with creatinine levels above institutional upper limit of normal (ULN)

          -  RANDOMIZED PHASE II STUDY -- ARMS C AND D

          -  PHASE II: Patients must have histologically or cytologically confirmed metastatic
             adenocarcinoma of the pancreas with no prior systemic therapy for metastatic disease

          -  PHASE II: Patients must NOT have locally advanced disease

          -  PHASE II: Patients must have measurable disease outside of the primary tumor
             (pancreas) by RECIST 1.1 criteria; baseline measurements and evaluations of all sites
             of disease must be obtained =&lt; 4 weeks prior to randomization

          -  PHASE II: Previous neo-adjuvant or adjuvant treatment is allowed provided that there
             was no evidence of recurrent disease for at least 6 months after completion of
             neo-adjuvant/adjuvant treatment

          -  PHASE II: Patients may have had prior radiotherapy for metastatic disease as long as
             it was &gt; 4 weeks prior to randomization and the patient has recovered from adverse
             events associated with the radiotherapy

          -  PHASE II: Patients must NOT be taking current medications or substances that are
             inhibitors or inducers of CYP3A4

          -  PHASE II: Patients must NOT have received prior Wee1 inhibitors or AZD1775

          -  PHASE II: Patients must NOT have received gemcitabine or nab-paclitaxel in a
             metastatic setting

          -  PHASE II: Patients must NOT be receiving any other investigational agents concurrently
             and must not have received any other investigational agents =&lt; 4 weeks prior to
             randomization

          -  PHASE II: Patients must not have a pre-existing &gt; grade 1 motor or sensory neuropathy

          -  PHASE II: Patients must NOT have history of allergic reactions attributed to compounds
             of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775

          -  PHASE II: Patients must have ECOG performance status of 0 or 1

          -  PHASE II: Patients must have a life expectancy of &gt;= 12 weeks

          -  PHASE II: Patients must NOT have uncontrolled serious medical illness including, but
             not limited to, ongoing or active infection, cardiac arrhythmia, or psychiatric
             illness that would limit compliance with study requirements

          -  PHASE II: Patients must be able to swallow capsules whole

          -  PHASE II: Patients with biliary stents are allowed

          -  PHASE II: Patients must NOT have previous or concurrent malignancy; exceptions are
             made for patients who meet any of the following conditions:

               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in situ)
                  â€¢ Prior malignancy completely excised or removed and patient has been
                  continuously disease free for &gt; 5 years

          -  PHASE II: Patients must be able to tolerate CT, MRI or PET imaging including contrast
             agents

          -  PHASE II: Women must not be pregnant or breast-feeding

               -  Females of childbearing potential must have a blood test or urine study within 5
                  days prior to randomization to rule out pregnancy; a female of childbearing
                  potential is any woman, regardless of sexual orientation or whether they have
                  undergone tubal ligation, who meets the following criteria: 1) has not undergone
                  a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any
                  time in the preceding 24 consecutive months)

          -  PHASE II: Women of child-bearing potential and men must agree to use adequate
             contraception (hormonal and barrier method of birth control; two barrier methods of
             birth control; abstinence) for the duration of study treatment and for 3 months after
             the last dose of study treatment; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately; should a man impregnate or suspect that he has impregnated a woman while
             participating in this study, he should inform his treating physician immediately

          -  PHASE II: Leukocytes &gt;= 3,000/mcL

          -  PHASE II: Absolute neutrophil count &gt;= 1,500/mcL

          -  PHASE II: Hemoglobin &gt;= 9 g/dL

          -  PHASE II: Platelets &gt;= 100,000/mcL

          -  PHASE II: Total bilirubin =&lt; 1.5 institutional upper limit of normal (ULN)

          -  PHASE II: AST (SGOT)/ALT (SGPT) =&lt; 3 X institutional upper limit of normal (ULN) or =&lt;
             5 X ULN if the patient has liver metastases

          -  PHASE II: Creatinine =&lt; 1.5 mg/dL or creatinine clearance (Cockcroft-Gault) &gt;= 60
             mL/min for patients with creatinine levels above institutional upper limit of normal
             (ULN)

          -  PHASE II: For participation in the imaging research studies, patients must meet the
             additional following criteria:

          -  PHASE II: The patient is participating in the trial at an institutional which has
             agreed to perform the imaging research studies, completed the American College of
             Radiation Imaging Network (ACRIN) defined scanner qualification procedures and
             received ACRIN approval

          -  PHASE II: The patient has consented in writing to participate in one of the imaging
             research studies

          -  PHASE II: The patient meets the criteria required for the imaging study in which the
             site is participating:

               -  NOTE: Eligibility for participating in either imaging sub-study will depend on
                  the availability of the imaging sub-study at a particular institution

               -  For participation in the FDG-PET sub-study:

                    -  Patients must NOT have poorly controlled diabetes (defined as fasting
                       glucose level &gt;= 200 mg/dL) despite efforts to improve glucose control by
                       fasting duration and adjustment of medications

                    -  Patient must NOT weigh more than the maximum weight limit for the PET table

                    -  Patients must have an evaluable lesion of &gt; 20 mm in size on standard
                       practice imaging study as assessed by site (either primary pancreas mass or
                       metastasis)

               -  For participation in the FLT-PET sub-study:

                    -  Patients must be able to lie still for a 1.5 hour PET scan.

                    -  Patient must NOT have a history of allergic reaction attributable to
                       compounds of similar chemical or biologic composition to 18F-fluorothymidine

                    -  Patient must NOT weigh more than the maximum weight limit for the PET table

                    -  Patients must have an evaluable lesion in the pancreas &gt; 20 mm in size on
                       standard practice imaging study as assessed by site (lesion must be likely
                       primary adenocarcinoma of the pancreas that is not primarily fibrotic or
                       mucinous in nature)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Eads</last_name>
    <role>Principal Investigator</role>
    <affiliation>ECOG-ACRIN Cancer Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

